Jan Nilsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7062445/publications.pdf

Version: 2024-02-01

28190 34900 11,528 215 55 98 h-index citations g-index papers 219 219 219 12317 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High levels of autoantibodies against apoB100 p210 are associated with lower incidence of atrial fibrillation in women. Journal of Internal Medicine, 2022, 291, 207-217.	2.7	3
2	Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture–prone atherosclerotic plaques. European Heart Journal, 2022, 43, 1864-1877.	1.0	27
3	Soluble CD40 receptor is a biomarker of the burden of carotid artery atherosclerosis in subjects at high cardiovascular risk. Atherosclerosis, 2022, 343, 1-9.	0.4	7
4	Osteomodulin Gene Expression Is Associated With Plaque Calcification, Stability, and Fewer Cardiovascular Events in the CPIP Cohort. Stroke, 2022, 53, STROKEAHA121037223.	1.0	5
5	Proteomic Profiles of Body Mass Index and Waist-to-Hip Ratio and Their Role in Incidence of Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2982-e2990.	1.8	8
6	Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events. Atherosclerosis, 2022, 355, 8-14.	0.4	2
7	Circulating Vimentin Is Associated With Future Incidence of Stroke in a Population-Based Cohort Study. Stroke, 2021, 52, 937-944.	1.0	9
8	Methodological considerations for identifying multiple plasma proteins associated with all-cause mortality in a population-based prospective cohort. Scientific Reports, 2021, 11, 6734.	1.6	2
9	The associations between red cell distribution width and plasma proteins in a general population. Clinical Proteomics, 2021, 18, 12.	1.1	2
10	Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes. Diabetes Care, 2021, 44, 1402-1409.	4.3	1
11	Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice. Scientific Reports, 2021, 11, 9022.	1.6	14
12	Long-Haul Post–COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome. JACC: Case Reports, 2021, 3, 573-580.	0.3	141
13	The novel collagen matrikine, endotrophin, is associated with mortality and cardiovascular events in patients with atherosclerosis. Journal of Internal Medicine, 2021, 290, 179-189.	2.7	11
14	Plasma Protein Profile of Carotid Artery Atherosclerosis and Atherosclerotic Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1777-1788.	1.1	18
15	Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes. Hypertension, 2021, 78, 40-50.	1.3	4
16	Promoting athero-protective immunity by vaccination with low density lipoprotein-derived antigens. Atherosclerosis, 2021, 335, 89-97.	0.4	4
17	Plaque Vulnerability Index Predicts Cardiovascular Events: A Histological Study of an Endarterectomy Cohort. Journal of the American Heart Association, 2021, 10, e021038.	1.6	17
18	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021, 144, 1295-1307.	1.6	75

#	Article	IF	CITATIONS
19	Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype. Journal of Stroke, 2021, 23, 367-376.	1.4	9
20	Reply by Authors. Journal of Urology, 2021, 206, 959-959.	0.2	0
21	Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascular Pharmacology, 2021, 140, 106863.	1.0	4
22	Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer. Journal of Urology, 2021, 206, 952-959.	0.2	5
23	Carotid atherosclerosis, changes in tissue remodeling and repair in patients with aortic coarctation. Atherosclerosis, 2021, 335, 47-52.	0.4	2
24	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nature Communications, 2021, 12, 6486.	5.8	31
25	Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages. Atherosclerosis, 2020, 296, 74-82.	0.4	14
26	Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature Metabolism, 2020, 2, 1135-1148.	5.1	327
27	The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death. Atherosclerosis, 2020, 313, 88-95.	0.4	10
28	Evidence for a protective role of placental growth factor in cardiovascular disease. Science Translational Medicine, 2020, 12 , .	5.8	12
29	Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. European Heart Journal, 2020, 41, 2938-2948.	1.0	22
30	Identification of Inflammatory and Disease-Associated Plasma Proteins that Associate with Intake of Added Sugar and Sugar-Sweetened Beverages and Their Role in Type 2 Diabetes Risk. Nutrients, 2020, 12, 3129.	1.7	12
31	Imaging of the vulnerable carotid plaque. Neurology, 2020, 94, 922-932.	1.5	30
32	Plasma Homocysteine and Cardiovascular Organ Damage in a Population with a High Prevalence of Risk Factors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2815-e2824.	1.8	6
33	S100A9 Links Inflammation and Repair in Myocardial Infarction. Circulation Research, 2020, 127, 664-676.	2.0	101
34	Developing a vaccine against atherosclerosis. Nature Reviews Cardiology, 2020, 17, 451-452.	6.1	15
35	The plasma protein profile and cardiovascular risk differ between intima-media thickness of the common carotid artery and the bulb: A meta-analysis and a longitudinal evaluation. Atherosclerosis, 2020, 295, 25-30.	0.4	18
36	Exploring the role of extracellular matrix proteins to develop biomarkers of plaque vulnerability and outcome. Journal of Internal Medicine, 2020, 287, 493-513.	2.7	43

#	Article	IF	CITATIONS
37	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. JACC: CardioOncology, 2020, 2, 70-81.	1.7	30
38	Vaccination Strategies and Immune Modulation of Atherosclerosis. Circulation Research, 2020, 126, 1281-1296.	2.0	49
39	Surgical exploration without resection in pancreatic and periampullary tumors: report from a national database. Scandinavian Journal of Surgery, 2020, 110, 145749692091366.	1.3	1
40	Antiâ€ApoAâ€I IgG antibodies are not associated with carotid artery disease progression and firstâ€time cardiovascular events in middleâ€aged individuals. Journal of Internal Medicine, 2019, 285, 49-58.	2.7	4
41	Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. European Heart Journal, 2019, 40, 2713-2723.	1.0	89
42	sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events. Stroke, 2019, 50, 1989-1996.	1.0	28
43	The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. Atherosclerosis, 2019, 287, 16-23.	0.4	21
44	Circulating HER2/ErbB2 Levels Are Associated With Increased Incidence of Diabetes: A Population-Based Cohort Study. Diabetes Care, 2019, 42, 1582-1588.	4.3	16
45	Cardiovascular organ damage in type 2 diabetes mellitus: the role of lipids and inflammation. Cardiovascular Diabetology, 2019, 18, 61.	2.7	44
46	Lack of Ability to Present Antigens on Major Histocompatibility Complex Class II Molecules Aggravates Atherosclerosis in ApoE ^{â^'/â^'} Mice. Circulation, 2019, 139, 2554-2566.	1.6	35
47	Activation of immune responses against the basement membrane component collagen type IV does not affect the development of atherosclerosis in ApoE-deficient mice. Scientific Reports, 2019, 9, 5964.	1.6	6
48	High Levels of Soluble Lectinlike Oxidized Lowâ€Density Lipoprotein Receptorâ€1 Are Associated With Carotid Plaque Inflammation and Increased Risk of Ischemic Stroke. Journal of the American Heart Association, 2019, 8, e009874.	1.6	37
49	3043Endotrophin, a fragment of collagen type VI, is correlated to IMT and associated with cardiovascular events in patients with atherosclerosis and diabetes: the IMI-SUMMIT cohort. European Heart Journal, 2019, 40, .	1.0	0
50	Associations of Interleukin-5 With Plaque Development and Cardiovascular Events. JACC Basic To Translational Science, 2019, 4, 891-902.	1.9	16
51	A biomarker of collagen type I degradation is associated with cardiovascular events and mortality in patients with atherosclerosis. Journal of Internal Medicine, 2019, 285, 118-123.	2.7	13
52	Elevated circulating effector memory T cells but similar levels of regulatory T cells in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes and Vascular Disease Research, 2019, 16, 270-280.	0.9	29
53	Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke. Heart, 2019, 105, 553-558.	1.2	29
54	Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer–Cardiovascular Cohort. Diabetologia, 2019, 62, 78-86.	2.9	71

#	Article	IF	CITATIONS
55	Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death. Cytokine, 2019, 122, 154208.	1.4	7
56	Plasma Concentration of Caspase-8 Is Associated With Short Sleep Duration and the Risk of Incident Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1592-1600.	1.8	5
57	Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. Atherosclerosis, 2018, 270, 1-7.	0.4	27
58	Development and Validation of a Path Length Calculation for Carotid–Femoral Pulse Wave Velocity Measurement. Hypertension, 2018, 71, 937-945.	1.3	19
59	Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques. European Heart Journal, 2018, 39, 2301-2310.	1.0	104
60	Interleukin-25 (IL-25) has a protective role in atherosclerosis development in the aortic arch in mice. Journal of Biological Chemistry, 2018, 293, 6791-6801.	1.6	14
61	IL-1R and MyD88 signalling in CD4+ T cells promote Th17 immunity and atherosclerosis. Cardiovascular Research, 2018, 114, 180-187.	1.8	44
62	Markers of Basement Membrane Remodeling Are Associated With Higher Mortality in Patients With Known Atherosclerosis. Journal of the American Heart Association, 2018, 7, e009193.	1.6	11
63	B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apolipoprotein E deficient mice. Vascular Pharmacology, 2018, 111, 54-61.	1.0	6
64	Coronary Artery Disease in Systemic Lupus Erythematosus. American Journal of the Medical Sciences, 2018, 356, 411-412.	0.4	0
65	Hyperglycemia does not affect tissue repair responses in shear stress-induced atherosclerotic plaques in ApoEâ ⁻ '/â ⁻ ' mice. Scientific Reports, 2018, 8, 7530.	1.6	1
66	Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. Diabetes Care, 2018, 41, 2212-2219.	4.3	28
67	Interleukin-25 reduces Th17 cells and inflammatory responses in human peripheral blood mononuclear cells. Human Immunology, 2018, 79, 685-692.	1.2	5
68	Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. Journal of Internal Medicine, 2018, 284, 377-387.	2.7	144
69	Vaccination against Tâ€cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. Journal of Internal Medicine, 2017, 281, 383-397.	2.7	51
70	Recent advances on CD4 + T cells in atherosclerosis and its implications for therapy. European Journal of Pharmacology, 2017, 816, 58-66.	1.7	33
71	ADAMTS-7 is associated with a high-risk plaque phenotype in human atherosclerosis. Scientific Reports, 2017, 7, 3753.	1.6	30
72	Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis. International Journal of Cardiology, 2017, 241, 430-436.	0.8	24

#	Article	IF	Citations
73	Atherosclerotic plaque vulnerability in the statin era. European Heart Journal, 2017, 38, 1638-1644.	1.0	67
74	FADD, Caspase-3, and Caspase-8 and Incidence of Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 983-989.	1.1	21
75	oxLDL antibody inhibits MCPâ€l release in monocytes/macrophages by regulating Ca ²⁺ /K ⁺ channel flow. Journal of Cellular and Molecular Medicine, 2017, 21, 929-940.	1.6	13
76	Autoantibodies against aldehydeâ€modified collagen type <scp>IV</scp> are associated with risk of development of myocardial infarction. Journal of Internal Medicine, 2017, 282, 496-507.	2.7	5
77	Plasma stem cell factor levels are associated with risk of cardiovascular disease and death. Journal of Internal Medicine, 2017, 282, 508-521.	2.7	27
78	Eosinophil Cationic Protein, Carotid Plaque, and Incidence of Stroke. Stroke, 2017, 48, 2686-2692.	1.0	16
79	Elevated Markers of Death Receptor-Activated Apoptosis are Associated with Increased Risk for Development of Diabetes and Cardiovascular Disease. EBioMedicine, 2017, 26, 187-197.	2.7	43
80	P1451Gender related differences in echocardiographic findings post heart transplantation -Impact of sex-mismatch on biventricular function. European Heart Journal, 2017, 38, .	1.0	0
81	Decreased levels of stem cell factor in subjects with incident coronary events. Journal of Internal Medicine, 2016, 279, 180-191.	2.7	15
82	Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1132-1140.	1.1	129
83	Can Antibodies Protect Us Against Cardiovascular Disease?. EBioMedicine, 2016, 9, 29-30.	2.7	8
84	Endarterectomy patients with elevated levels of circulating IL-16 have fewer cardiovascular events during follow-up. Cytokine, 2016, 85, 137-139.	1.4	6
85	<scp>CD</scp> 4 ⁺ <scp>CD</scp> 56 ⁺ natural killer Tâ€like cells secreting interferonâ€l³ are associated with incident coronary events. Journal of Internal Medicine, 2016, 279, 78-88.	2.7	6
86	Regulatory T cells: getting to the heart of the matter. Journal of Internal Medicine, 2016, 279, 60-62.	2.7	0
87	Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE \hat{a} mice. Scientific Reports, 2016, 6, 26220.	1.6	40
88	Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. BMC Cardiovascular Disorders, 2016, 16, 171.	0.7	13
89	Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 765-771.	1.1	43
90	Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes. Stroke, 2016, 47, 1140-1143.	1.0	11

#	Article	IF	Citations
91	Determining carotid plaque vulnerability using ultrasound center frequency shifts. Atherosclerosis, 2016, 246, 293-300.	0.4	14
92	The changing face of atherosclerotic plaque inflammation. Journal of Internal Medicine, 2015, 278, 430-432.	2.7	4
93	Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European crossâ€sectional study. Journal of Internal Medicine, 2015, 278, 291-302.	2.7	38
94	Low Elastin Content of Carotid Plaques Is Associated with Increased Risk of Ipsilateral Stroke. PLoS ONE, 2015, 10, e0121086.	1.1	12
95	Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. Journal of Internal Medicine, 2015, 278, 494-506.	2.7	49
96	Concurrent biliary drainage and portal vein embolization in preparation for extended hepatectomy in patients with biliary cancer. Acta Radiologica Open, 2015, 4, 205846011557912.	0.3	4
97	Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities. Hpb, 2015, 17, 983-987.	0.1	22
98	Low Levels of IgM Antibodies against an Advanced Glycation Endproduct–Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects. Journal of Immunology, 2015, 195, 3020-3025.	0.4	30
99	Chronic Inflammation and Atherosclerosis. , 2015, , 157-167.		5
100	Autoantibodies against basement membrane collagen type IV are associated with myocardial infarction. IJC Heart and Vasculature, 2015, 6, 42-47.	0.6	8
101	Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy. Atherosclerosis, 2015, 239, 289-294.	0.4	17
102	Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges. Journal of Internal Medicine, 2015, 278, 507-519.	2.7	21
103	Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 464-475.	0.8	32
104	Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis, 2015, 241, 443-449.	0.4	40
105	Increased aldehyde-modification of collagen type IV in symptomatic plaques – A possible cause of endothelial dysfunction. Atherosclerosis, 2015, 240, 26-32.	0.4	13
106	High Plasma Levels of Heparin-Binding Epidermal Growth Factor Are Associated With a More Stable Plaque Phenotype and Reduced Incidence of Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 222-228.	1.1	15
107	Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clinical and Experimental Immunology, 2015, 181, 417-426.	1.1	43
108	IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice. Atherosclerosis, 2015, 242, 506-514.	0.4	43

#	Article	IF	CITATIONS
109	Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1723-1731.	1.1	86
110	Expression of fibromodulin in carotid atherosclerotic plaques is associated with diabetes and cerebrovascular events. Atherosclerosis, 2015, 241, 701-708.	0.4	11
111	Human Carotid Plaques With High Levels of Interleukin-16 Are Associated With Reduced Risk for Cardiovascular Events. Stroke, 2015, 46, 2748-2754.	1.0	13
112	IL-25 Inhibits Atherosclerosis Development in Apolipoprotein E Deficient Mice. PLoS ONE, 2015, 10, e0117255.	1.1	40
113	Circulating Autoantibodies against the Apolipoprotein B-100 Peptides p45 and p210 in Relation to the Occurrence of Carotid Plaques in 64-Year-Old Women. PLoS ONE, 2015, 10, e0120744.	1.1	18
114	Non-invasive imaging of microcirculation: a technology review. Medical Devices: Evidence and Research, 2014, 7, 445.	0.4	54
115	Laser speckle contrast imaging for intraoperative assessment of liver microcirculation: a clinical pilot study. Medical Devices: Evidence and Research, 2014, 7, 257.	0.4	32
116	Vaccine for Atherosclerosis. Journal of the American College of Cardiology, 2014, 64, 2779-2791.	1.2	70
117	Impaired Fibrous Repair. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2143-2150.	1.1	49
118	Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 202-210.	1.1	90
119	Plasma levels of highâ€sensitive <scp>C</scp> â€reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques. Journal of Internal Medicine, 2014, 275, 127-133.	2.7	17
120	Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. European Urology, 2014, 65, 565-573.	0.9	276
121	Circulating CD40 ⁺ and CD86 ⁺ B Cell Subsets Demonstrate Opposing Associations With Risk of Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 211-218.	1.1	44
122	Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis, 2014, 232, 242-248.	0.4	27
123	Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoEâ^'/â^' mice. Cardiovascular Research, 2014, 103, 304-312.	1.8	18
124	Microcirculation changes during liver resection â€" A clinical study. Microvascular Research, 2014, 94, 47-51.	1.1	19
125	Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoprotein. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 172-80.	1.0	1
126	Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis $\hat{a}\in$ A review of the experimental evidence. Atherosclerosis, 2013, 227, 9-17.	0.4	46

#	Article	IF	CITATIONS
127	Vaccines against atherosclerosis. Expert Review of Vaccines, 2013, 12, 311-321.	2.0	23
128	T-Helper 2 Immunity Is Associated With Reduced Risk of Myocardial Infarction and Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 637-644.	1.1	93
129	Fibromodulin Deficiency Reduces Low-Density Lipoprotein Accumulation in Atherosclerotic Plaques in Apolipoprotein E–Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 354-361.	1.1	25
130	Association between <scp>CD</scp> 8 ⁺ Tâ€eell subsets and cardiovascular disease. Journal of Internal Medicine, 2013, 274, 41-51.	2.7	50
131	Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists Journal of Clinical Oncology, 2013, 31, 42-42.	0.8	4
132	Apolipoprotein B100 autoimmunity and atherosclerosis – disease mechanisms and therapeutic potential. Current Opinion in Lipidology, 2012, 23, 422-428.	1.2	42
133	Regulatory T-Cell Response to Apolipoprotein B100–Derived Peptides Reduces the Development and Progression of Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 605-612.	1.1	113
134	Elevated CD14 ⁺⁺ CD16 ^{â^'} Monocytes Predict Cardiovascular Events. Circulation: Cardiovascular Genetics, 2012, 5, 122-131.	5.1	217
135	Increased Inflammation in Atherosclerotic Lesions of Diabetic <i>Akita-LDLr</i> ^{â°'/â°'} Mice Compared to Nondiabetic <i>LDLr</i> ^{â°'/â°'} Mice. Experimental Diabetes Research, 2012, 2012, 1-12.	3.8	21
136	Evidence Supporting a Key Role of Lp-PLA2-Generated Lysophosphatidylcholine in Human Atherosclerotic Plaque Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1505-1512.	1.1	157
137	Low Levels of Circulating CD4+FoxP3+ T Cells Are Associated With an Increased Risk for Development of Myocardial Infarction But Not for Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2000-2004.	1.1	139
138	Lymphocytes in atherosclerosis. Clinica Chimica Acta, 2012, 413, 1562-1568.	0.5	56
139	Mobilization of Regulatory T Cells in Response to Carotid Injury Does Not Influence Subsequent Neointima Formation. PLoS ONE, 2012, 7, e51556.	1.1	8
140	Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Molecular Medicine, 2012, 4, 564-576.	3.3	101
141	High levels of IgM against methylglyoxalâ€modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. Journal of Internal Medicine, 2012, 271, 82-89.	2.7	28
142	TAP1-Deficiency Does Not Alter Atherosclerosis Development in Apoeâ^'/â^' Mice. PLoS ONE, 2012, 7, e33932.	1.1	34
143	Immunization of apoEâ \in "/â \in " mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis. Cardiovascular Research, 2011, 91, 528-536.	1.8	34
144	Immunization with cationized BSA inhibits progression of disease in ApoBec-1/LDL receptor deficient mice with manifest atherosclerosis. Immunobiology, 2011, 216, 663-669.	0.8	9

#	Article	IF	Citations
145	Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. Journal of Internal Medicine, 2011, 269, 546-556.	2.7	82
146	Food patterns, inflammation markers and incidence of cardiovascular disease: the Malm \tilde{A}^\P Diet and Cancer study. Journal of Internal Medicine, 2011, 270, 365-376.	2.7	38
147	CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe-/- mice. BMC Immunology, 2010, 11, 58.	0.9	74
148	Weak associations between human leucocyte antigen genotype and acute myocardial infarction. Journal of Internal Medicine, 2010, 268, 50-58.	2.7	36
149	Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 946-952.	1.1	179
150	Short Communication: Dating Components of Human Atherosclerotic Plaques. Circulation Research, 2010, 106, 1174-1177.	2.0	34
151	FcÎ ³ RIIB Inhibits the Development of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Journal of Immunology, 2010, 184, 2253-2260.	0.4	44
152	The B Cell in Atherosclerosis: Teaming Up with the Bad Guys?. Clinical Chemistry, 2010, 56, 1789-1791.	1.5	4
153	Concomitant deletions of tumor suppressor genes <i>MEN1</i> and <i>AIP</i> are essential for the pathogenesis of the brown fat tumor hibernoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21122-21127.	3.3	64
154	Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment. Journal of the American College of Cardiology, 2010, 55, 1362-1369.	1.2	58
155	Immune responses against aldehyde-modified laminin accelerate atherosclerosis in Apoeâ^'/â^' mice. Atherosclerosis, 2010, 212, 457-465.	0.4	23
156	Atheroprotective Effects of Alum Are Associated With Capture of Oxidized LDL Antigens and Activation of Regulatory T Cells. Circulation Research, 2009, 104, e62-70.	2.0	59
157	Regulatory T Cells and the Control of Modified Lipoprotein Autoimmunity-Driven Atherosclerosis. Trends in Cardiovascular Medicine, 2009, 19, 272-276.	2.3	36
158	Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia, 2009, 52, 1426-1433.	2.9	55
159	Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. Journal of Internal Medicine, 2009, 265, 593-603.	2.7	20
160	Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. Journal of Internal Medicine, 2009, 266, 221-231.	2.7	35
161	Autoimmunity in atherosclerosis: a protective response losing control?. Journal of Internal Medicine, 2008, 263, 464-478.	2.7	136
162	Introduction: Atherosclerosis as inflammation: a controversial concept becomes accepted. Journal of Internal Medicine, 2008, 263, 462-463.	2.7	22

#	Article	IF	CITATIONS
163	Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo Bâ€100 transgenic mice without inducing an increase in peptideâ€specific antibodies. Journal of Internal Medicine, 2008, 264, 563-570.	2.7	86
164	Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. Biochemical and Biophysical Research Communications, 2008, 370, 348-352.	1.0	83
165	High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. European Heart Journal, 2008, 29, 2218-2226.	1.0	89
166	Inflammation and immunity in diabetic vascular complications. Current Opinion in Lipidology, 2008, 19, 519-524.	1.2	34
167	Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease. Current Pharmaceutical Design, 2007, 13, 1021-1030.	0.9	43
168	Association Between IgM Against an Aldehyde-Modified Peptide in Apolipoprotein B-100 and Progression of Carotid Disease. Stroke, 2007, 38, 1495-1500.	1.0	45
169	Involvement of the CD1d–Natural Killer T Cell Pathway in Neointima Formation After Vascular Injury. Circulation Research, 2007, 101, e83-9.	2.0	20
170	Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis, 2007, 190, 298-305.	0.4	32
171	Autoantibody against the amino acid sequence 661–680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis, 2007, 194, e188-e192.	0.4	51
172	Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1â^²/â^²/Low-Density Lipoprotein Receptorâ^²/â^³Mice. Journal of the American College of Cardiology, 2007, 50, 2313-2318.	1.2	153
173	Simvastatin stimulates macrophage interleukin- $1\hat{l}^2$ secretion through an isoprenylation-dependent mechanism. Vascular Pharmacology, 2007, 46, 91-96.	1.0	26
174	Oxidized lipoprotein autoimmunity: an emerging drug target in cardiovascular disease. Future Lipidology, 2006, 1, 321-330.	0.5	0
175	Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide. Journal of Lipid Research, 2006, 47, 2049-2054.	2.0	12
176	CRPâ€"Marker or Maker of Cardiovascular Disease?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1527-1528.	1.1	66
177	Immunomodulation of atherosclerosis with a vaccine. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 639-646.	3.3	46
178	Immunomodulation of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 18-28.	1,1	121
179	Very low density lipoprotein potentiates tumor necrosis factor-α expression in macrophages. Atherosclerosis, 2005, 179, 247-254.	0.4	29
180	Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E ($\hat{a}^{-2}/\hat{a}^{-2}$) mice. Biochemical and Biophysical Research Communications, 2005, 338, 1982-1989.	1.0	69

#	Article	IF	CITATIONS
181	Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity, 2005, 38, 171-179.	1.2	83
182	Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis. Circulation, 2004, 110, 2047-2052.	1.6	182
183	Elastin and Calcium Rather Than Collagen or Lipid Content Are Associated With Echogenicity of Human Carotid Plaques. Stroke, 2004, 35, 2795-2800.	1.0	63
184	Atherosclerosis. Autoimmunity, 2004, 37, 351-355.	1.2	2
185	Inhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2137-2142.	1.1	435
186	Ultrasound in Lund - three world premieres. Clinical Physiology and Functional Imaging, 2004, 24, 137-140.	0.5	4
187	Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism: Clinical and Experimental, 2004, 53, 1436-1442.	1.5	81
188	Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (\hat{a}^2/\hat{a}^2) mice. Atherosclerosis, 2004, 176, 27-35.	0.4	48
189	Will autoantibodies help to determine severity and progression of atherosclerosis?. Current Opinion in Lipidology, 2004, 15, 499-503.	1.2	28
190	Autoantibodies against modified low-density lipoproteins in coronary artery disease. Atherosclerosis, 2003, 167, 347-353.	0.4	39
191	Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 879-884.	1.1	240
192	Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 872-878.	1.1	173
193	Changes Related to Age and Cerebrovascular Symptoms in the Extracellular Matrix of Human Carotid Plaques. Stroke, 2003, 34, 616-622.	1.0	60
194	Radiation response of hypoxic and generally heterogeneous tissues. International Journal of Radiation Biology, 2002, 78, 389-405.	1.0	24
195	Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques. Circulation, 2001, 103, 926-933.	1.6	942
196	Absence of EC-SOD Does Not Promote Atherogenesis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1387-1388.	1.1	1
197	Oxidized LDL and Lysophosphatidylcholine Stimulate Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 3025-3032.	1.1	46
198	Presence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1218-1222.	1.1	359

#	Article	IF	CITATIONS
199	A Common Functional Polymorphism (C->A Substitution at Position -863) in the Promoter Region of the Tumour Necrosis Factor-Â (TNF-Â) Gene Associated With Reduced Circulating Levels of TNF-Â. Human Molecular Genetics, 1999, 8, 1443-1449.	1.4	307
200	Evidence for a role of tumor necrosis factor \hat{l}_{\pm} in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism: Clinical and Experimental, 1998, 47, 113-118.	1.5	170
201	An Animal Model to Study Local Oxidation of LDL and Its Biological Effects in the Arterial Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 884-893.	1.1	79
202	Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis, 1997, 130, 17-27.	0.4	159
203	Immunization With Homologous Oxidized Low Density Lipoprotein Reduces Neointimal Formation After Balloon Injury in Hypercholesterolemic Rabbits. Journal of the American College of Cardiology, 1997, 30, 1886-1891.	1.2	101
204	Extracellular sodium dismutase: does it have a role in cardiovascular disease?. Journal of Internal Medicine, 1997, 242, 1-3.	2.7	5
205	Tumor Necrosis Factor-α Activates Smooth Muscle Cell Migration in Culture and Is Expressed in the Balloon-Injured Rat Aorta. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 490-497.	1.1	128
206	Active Oxygen Species and Lysophosphatidylcholine Are Involved in Oxidized Low Density Lipoprotein Activation of Smooth Muscle Cell DNA Synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 194-200.	1.1	73
207	25-HYDROXYCHOLESTEROL INDUCES APOPTOSIS IN HUMAN AORTIC SMOOTH MUSCLE CELLS. Biochemical Society Transactions, 1996, 24, 616S-616S.	1.6	0
208	Autocrine Induction of DNA Synthesis by Mechanical Injury of Cultured Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 187-193.	1.1	19
209	Effect of Immunization With Homologous LDL and Oxidized LDL on Early Atherosclerosis in Hypercholesterolemic Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1074-1079.	1.1	277
210	The Susceptibility of Low Density Lipoprotein to Chemical Oxidation is Closely Related to Proneness to Biological Modification. Free Radical Research, 1995, 23, 581-592.	1.5	1
211	Lipid oxidation, vascular inflammation, and coronary atherosclerosis. Transplantation Proceedings, 1993, 25, 2063-4.	0.3	5
212	Induction of T-cell activation by oxidized low density lipoprotein Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 461-467.	3.8	213
213	Coupling between inositol phosphate formation and DNA synthesis in smooth muscle cells stimulated with neurokinin A. Journal of Cellular Physiology, 1988, 137, 141-145.	2.0	21
214	Smooth Muscle Cells in the Atherosclerotic Process. Acta Medica Scandinavica, 1987, 221, 25-31.	0.0	6
215	Growth factors and the pathogenesis of atherosclerosis. Atherosclerosis, 1986, 62, 185-199.	0.4	116